linux webcast |
||||
|
News for 17-Apr-24 Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General |
The Best linux webcast websiteAll the linux webcast information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best linux webcast site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
linux webcast
When you're shopping for linux webcast you've come to the right place. We're specialists in this linux webcast field. You can't find exactly what you're looking for on too many other sites, but you can here. Well maybe that's a slight exaggeration. We might not have got exactly what you're looking for - linux webcast - but we know the very best websites to get it from. All you have to do is follow the links below. They're the very best linux webcast sites you're going to find anywhere, and they're the ones we use ourselves when we want to get information or make a purchase. linux webcast
There are many people promoting linux webcast and some are not as forthright as they should be. The information both in print and on the Internet about linux webcast is widely mixed to say the least. As you spend a few minutes with us you will see that we have a very comprehensive index of linux webcast information and any question you have can be answered here. We know that your time is valuable and have made this linux webcast resource site easy to navigate and of great value to our visitors. a Cold; Starve a Tumor by: ARA Content
(ARA) - One of the most exciting developments in modern medicine has been the discovery that cancerous tumors have the potential of being "starved" out of existence, or at least into dormancy. Scientists, doctors and, of course, patients, are all anticipating the prospect that cancer patients may take a drug that will stop a tumor in its track by cutting off the blood supply that nourishes it. At the core of this medical breakthrough was the discovery that every tumor needs to "recruit" its own blood supply to flourish and grow. Scientists also found out that tumors actively "participated" in this process by secreting certain growth chemicals that would attract blood vessels to the tumor. Having identified this process, the next step was to determine if drugs could be created that could somehow arrest or reverse the progress of blood vessels amassing around a tumor. The result has been a highly dynamic and exciting area of medicine called anti-angiogenesis (meaning "against the formation of new blood vessels") that focuses on inhibiting the growth of cancer by developing drugs that will prevent tumors from growing in size. Currently, there are several drug companies that are on the cusp of introducing drugs that will work by the process of anti-angiogenesis. Generally speaking, the drugs seek to improve survival rates of cancer patients, as well as increase the length of time that patients survive. And unlike conventional cancer therapies that have punishing side effects, the new drugs seem to demonstrate few or no side effects for most people. Furthermore, some of the studies show that by utilizing both conventional treatments like radiation and/or chemotherapy in conjunction with anti-angiogenesis drugs, the cumulative effect is even more powerful. One highly regarded company that is at the forefront of developing anti-angiogenesis drugs is Aeterna Laboratories, based in Quebec, Canada and traded on the Nasdaq market under the ticker symbol, AELA. The company's premier product, Neovastat, is currently being tested in clinical trials for a variety of cancers including lung, renal (kidney) and multiple myeloma (bone marrow). The results for the renal and multiple myeloma tests are scheduled to wrap up by the end of 2002 and, if conclusive, will be submitted to the Federal Drug Administration for review. Out of all the drugs under development, Neovastat is unique because of its multi-functionality, which is its ability to shut down two pathways recognized as being responsible for promoting angiogenesis (in contrast to other drugs which just block one pathway). In clinical trials, Neovastat has been shown to have no side effects in most people. This is obviously a big advantage for people who know the agony of nausea, exhaustion and/or hair loss that can accompany chemotherapy drugs. In tests, Neovastat has been given to people in liquid oral form, generally the preferable form of drug delivery for patients. If you are a cancer patient interested in clinical trial participation, you can get information about current trials by calling (888)-349-3232 If you are an oncologist, please contact Claude Hariton, Ph.D., vice president of Clinical and Regulatory Affairs at (418) 652-8525 ext. 306. To learn more about anti-angiogenesis drugs and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com.
|
|||
|
http://www.medmeet.com/ |
||||
| Medical Newscast Medical Meetings Medical Presentations |